AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation
Molecular Therapy Oncology · 2026-06 · 34 (2) · 201216
DOI: 10.1016/j.omton.2026.201216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-06. Verfasst von Angela Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Clinical Pharmacology, The University of Auckland, Auckland 1023, New Zealand. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Hugh Green Foundation, Freemasons New Zealand.
Abstract (Originalsprache)
Glioblastoma (GBM) is a highly aggressive type of brain cancer associated with poor prognosis due to limited effective treatment options. Adeno-associated viral (AAV) vector-based gene therapy strategies have demonstrated promise in preclinical models of GBM, but inter- and intratumor cellular heterogeneity poses a challenge for tumor-specific targeting. Here, we screened a panel of 15 AAV serotypes against the widely used human GBM cell line U-87 MG, and five primary patient-derived GBM cell lines to characterize their transduction efficiencies. AAV1, AAV2, AAV1/2, AAV6, and AAV6.2 were the most efficient and consistent serotypes across cell lines, capable of differentially transducing CD44-expressing cells in culture, albeit non-selectively. Interestingly, we observed a reduction in cell number and proliferation in certain cell lines, which correlated with AAV transduction efficiency. This phenomenon was shown to be a cytostatic rather than cytotoxic effect on GBM cells, occurring independently of promoter sequence and transgene expression. The anti-proliferative effect was particularly pronounced in two patient-derived cell lines, where cell proliferation decreased by nearly 80%. Altogether, our results provide a foundation for future studies optimizing AAV-mediated transduction in the diverse GBM cell population and demonstrate the potential to harness the natural properties of AAV in treatment development for brain cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology & Clinical Pharmacology, The University of Auckland, Auckland 1023, New Zealand.
- Centre for Brain Research, The University of Auckland, Auckland 1023, New Zealand.
Förderung
- The Hugh Green Foundation
- Freemasons New Zealand
Zitieren
APA
Wu, A., Dumo, C. J., Cook, W. H., Richards, I., Macapagal Foliaki, J., Cooper, E., Fong, D. M., Mouravlev, A., Park, T. I., Dragunow, M., & Young, D. (2026). AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation. Molecular Therapy Oncology, 34(2), 201216. https://doi.org/10.1016/j.omton.2026.201216
Vancouver
Wu A, Dumo CJ, Cook WH, Richards I, Macapagal Foliaki J, Cooper E, et al. AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation. Molecular Therapy Oncology. 2026;34(2):201216. doi:10.1016/j.omton.2026.201216
BibTeX
@article{Wu2026,
author = {Wu, Angela and Dumo, Carina J and Cook, William H and Richards, Imogen and Macapagal Foliaki, Jena and Cooper, Elizabeth and Fong, Dahna M and Mouravlev, Alexandre and Park, Thomas I-H and Dragunow, Michael and Young, Deborah},
title = {AAV transduction of human glioblastoma cell lines induces perturbation in cell proliferation},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {2},
pages = {201216},
doi = {10.1016/j.omton.2026.201216}
}
EUVIMED